Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 29
Filter
1.
Endocrinol Diabetes Nutr ; 64 Suppl 1: 23-30, 2017 Mar.
Article in English, Spanish | MEDLINE | ID: mdl-28440762

ABSTRACT

Thyroid nodule detection has increased with widespread use of ultrasound, which is currently the main tool for detection, monitoring, diagnosis and, in some instances, treatment of thyroid nodules. Knowledge of ultrasound and adequate instruction on its use require a position statement by the scientific societies concerned. The working groups on thyroid cancer and ultrasound techniques of the Spanish Society of Endocrinology and Nutrition have promoted this document, based on a thorough analysis of the current literature, the results of multicenter studies and expert consensus, in order to set the requirements for the best use of ultrasound in clinical practice. The objectives include the adequate framework for use of thyroid ultrasound, the technical and legal requirements, the clinical situations in which it is recommended, the levels of knowledge and learning processes, the associated responsibility, and the establishment of a standardized reporting of results and integration into hospital information systems and endocrinology units.


Subject(s)
Endocrinology/organization & administration , Hospital Units , Thyroid Diseases/diagnostic imaging , Ultrasonography , Accreditation/standards , Biopsy, Fine-Needle , Certification/standards , Data Curation , Endocrinology/legislation & jurisprudence , Endocrinology/methods , Equipment Safety/standards , Hospital Information Systems , Hospital Units/legislation & jurisprudence , Hospital Units/organization & administration , Hospital Units/standards , Humans , Hyperparathyroidism, Primary/diagnostic imaging , Medical Records , Practice Guidelines as Topic , Prevalence , Thyroid Neoplasms/diagnostic imaging , Thyroid Nodule/diagnostic imaging , Thyroid Nodule/epidemiology , Thyroid Nodule/pathology , Ultrasonography/instrumentation , Ultrasonography/methods , Ultrasonography/standards
3.
An. pediatr. (2003. Ed. impr.) ; 84(3): 178.e1-178.e7, mar. 2016. tab
Article in Spanish | IBECS | ID: ibc-147747

ABSTRACT

La obesidad infantil determina un riesgo elevado de enfermedad cardiovascular. Este artículo realiza una actualización sobre el papel que los factores dietéticos tienen sobre el desarrollo y la prevención de la obesidad en este grupo de edad. Según la evidencia científica, las recomendaciones recogidas son: promover el consumo de hidratos de carbono de absorción lenta y disminuir aquellos con índice glucémico alto, evitar el consumo de bebidas azucaradas, limitar el consumo de grasas a un 30% de las calorías totales diarias y el de grasas saturadas a un 7-10%, reducir la ingesta de colesterol, evitar durante el primer año las fórmulas con alto contenido proteico, aumentar la ingesta de fibra, reducir el aporte de sodio y realizar al menos 4 comidas al día evitando el consumo regular de comida rápida y de snacks


Childhood obesity is associated with a high risk of cardiovascular disease and early mortality. This paper summarises the currently available evidence on the implications of dietary factors on the development and prevention of obesity in paediatric patients. Evidence-based recommendations are: promote the consumption of slowly absorbed carbohydrates and reduce those with a high-glycaemic-index, avoid intake of sugar-sweetened beverages. Fat may provide up to 30-35% of the daily energy intake and saturated fat should provide no more than 10% of daily energy intake; reduce cholesterol intake, avoid formula milk with a high protein content during the first year; promote higher fibre content in the diet, reduce sodium intake, and have at least four meals a day, avoiding regular consumption of fast food and snacks


Subject(s)
Humans , Male , Female , Child , Pediatric Obesity/complications , Pediatric Obesity/epidemiology , Pediatric Obesity/prevention & control , Endocrine System Diseases/epidemiology , Endocrine System Diseases/prevention & control , Risk Factors , Feeding Behavior/physiology , Energy Metabolism/physiology , Energy Consumption/methods , Societies, Medical/organization & administration , Societies, Medical/standards , Endocrinology/legislation & jurisprudence , Endocrinology/standards , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/prevention & control , Body Mass Index , Micronutrients/therapeutic use
6.
J Diabetes Sci Technol ; 7(2): 350-5, 2013 Mar 01.
Article in English | MEDLINE | ID: mdl-23566992

ABSTRACT

Safety issues posed by driving with diabetes are primarily related to severe hypoglycemia, yet some public authorities rely on categorical restrictions on drivers with diabetes. This approach is misguided. Regulation of all drivers with diabetes, or all drivers using insulin, ignores the diversity of people with diabetes and fails to focus on the subpopulation posing the greatest risk. Advances in diabetes care technology and understanding of safety consequences of diabetes have expanded techniques available to limit risks of driving with diabetes. New means of insulin administration and blood glucose monitoring offer greater ease of anticipating and preventing hypoglycemia, and thus, limit driving risk for persons with diabetes. So too do less sophisticated steps taken by people with diabetes and the health care professionals they consult. These include adoption and endorsement of safety-sensitive behaviors, such as testing before a drive and periodic testing on longer trips. Overall, and in most individual cases, driving risks for persons with diabetes are less than those routinely tolerated by our society. Examples include freedom to drive in dangerous conditions and lax regulation of drivers in age and medical cohorts with elevated overall rates of driving mishaps. Data linking specific diabetes symptoms or features with driving risk are quite uncertain. Hence, there is much to recommend: a focus on technological advances, human precautions, and identifying individuals with diabetes with a specific history of driving difficulty. By contrast, available evidence does not support unfocused regulation of all or most drivers with diabetes.


Subject(s)
Accidents, Traffic/prevention & control , Automobile Driving/legislation & jurisprudence , Diabetes Mellitus , Accidents, Traffic/legislation & jurisprudence , Diabetes Mellitus/psychology , Diabetes Mellitus/therapy , Endocrinology/legislation & jurisprudence , Endocrinology/organization & administration , Humans , Hypoglycemia/complications , Hypoglycemia/prevention & control , Risk , Societies, Medical/legislation & jurisprudence
7.
J Clin Endocrinol Metab ; 98(4): 1376-87, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23463657

ABSTRACT

OBJECTIVE: The objective of the study was to evaluate the current state of clinical assays for estradiol in the context of their applications. PARTICIPANTS: The participants were appointed by the Council of The Endocrine Society and charged with attaining the objective using published data and expert opinion. EVIDENCE: Data were gathered from published sources via online databases (principally PubMed, Ovid MEDLINE, Google Scholar), and the clinical and laboratory experience of the participants. CONSENSUS PROCESS: The statement was an effort of the committee and was reviewed by each member. The Clinical Affairs Committee, the Council of The Endocrine Society, and JCEM reviewers reviewed the manuscript and made recommendations. CONCLUSIONS: The measurement of estradiol in biological fluids is important in human biology from cradle to grave. In addition to its centrality in sexual development, it has significant effects on skin, blood vessels, bone, muscle, coagulation, hepatic cells, adipose tissue, the kidney, the gastrointestinal tract, brain, lung, and pancreas. Alterations in its plasma concentration have been implicated in coronary artery disease, stroke, and breast cancer. Although modern immunoassays and liquid chromatography/tandem mass spectrometry-based methods for estradiol are reasonably well suited to the diagnosis and management of infertility (nonetheless, imprecision and method-to-method differences remain problematic), the very low concentrations that appear to be crucial in nonreproductive tissues are a separate and more difficult issue. Such levels of estradiol are too low to be routinely measured accurately or precisely, and further evolution of analytical methods and the way in which estradiol is standardized is needed.


Subject(s)
Diagnostic Techniques, Endocrine , Endocrinology/organization & administration , Estradiol/analysis , Societies, Medical , Diagnostic Errors , Diagnostic Techniques, Endocrine/standards , Endocrinology/legislation & jurisprudence , Estradiol/blood , Humans , Practice Guidelines as Topic , Professional Practice , Research Design
8.
J Clin Endocrinol Metab ; 97(12): 4293-301, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23185035

ABSTRACT

Diabetes affects more than 300 million individuals globally, contributing to significant morbidity and mortality worldwide. As the incidence and prevalence of diabetes continue to escalate with the force of an approaching tsunami, it is imperative that we better define the biological mechanisms causing both obesity and diabetes and identify optimal prevention and treatment strategies that will enable a healthier environment and calmer waters. New guidelines from the American Diabetes Association/European Association of the Study of Diabetes and The Endocrine Society encourage individualized care for each patient with diabetes, both in the outpatient and inpatient setting. Recent data suggest that restoration of normal glucose metabolism in people with prediabetes may delay progression to type 2 diabetes (T2DM). However, several large clinical trials have underscored the limitations of current treatment options once T2DM has developed, particularly in obese children with the disease. Prospects for reversing new-onset type 1 diabetes also appear limited, although recent clinical trials indicate that immunotherapy can delay the loss of ß-cell function, suggesting potential benefits if treatment is initiated earlier. Research demonstrating a role for the central nervous system in the development of obesity and T2DM, the identification of a new hormone that simulates some of the benefits of exercise, and the development of new ß-cell imaging techniques may provide novel therapeutic targets and biomarkers of early diabetes detection for optimization of interventions. Today's message is that a diabetes tsunami is imminent, and the only way to minimize the damage is to create an early warning system and improve interventions to protect those in its path.


Subject(s)
Diabetes Mellitus, Type 2/epidemiology , Algorithms , Clinical Trials as Topic , Diabetes Mellitus, Type 2/therapy , Endocrinology/legislation & jurisprudence , Endocrinology/methods , Endocrinology/organization & administration , Humans , Models, Biological , Patient-Centered Care/methods , Patient-Centered Care/trends , Practice Guidelines as Topic , Prevalence , Societies, Medical/legislation & jurisprudence
9.
J Clin Endocrinol Metab ; 97(12): 4549-58, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23043191

ABSTRACT

CONTEXT: More than two decades have passed since members from the American Thyroid Association (ATA), European Thyroid Association, and Japan Thyroid Association were surveyed on management practices for patients with hyperthyroidism due to Graves' disease (GD). OBJECTIVE: We sought to document current practices in the management of GD and compare these results both to those documented in earlier surveys and to practice recommendations made in the 2011 ATA/American Association of Clinical Endocrinologists (AACE) hyperthyroidism practice guidelines. Lastly, we sought to examine differences in GD management among international members of U.S.-based endocrine societies. METHODS: Members of The Endocrine Society (TES), ATA, and AACE were invited to participate in a web-based survey dealing with testing, treatment preference, and modulating factors in patients with GD. RESULTS: A total of 730 respondents participated in the survey, 696 of whom completed all sections. Respondents included 641 TES members, 330 AACE members, and 157 ATA members. The preferred mode of therapy in uncomplicated GD was antithyroid drugs (ATDs) by 53.9% of respondents, radioactive iodine (RAI) therapy by 45.0%, and thyroid surgery in 0.7%. Compared with 1991, fewer U.S. (59.7 vs. 69%) and European (13.3% vs. 25%) respondents would use RAI therapy. Methimazole and carbimazole were the preferred ATDs, with only 2.7% of respondents selecting propylthiouracil. Patients with Graves' ophthalmopathy were treated with ATDs (62.9%) or surgery (18.5%) and less frequently with RAI plus corticosteroids (16.9%) or RAI alone (1.9%). CONCLUSIONS: Striking changes have occurred in the management of GD over the past two decades, with a shift away from RAI and toward ATDs in patients with uncomplicated GD. Apparent international differences persist but should be interpreted with caution. Current practices diverge in some areas from recently published guidelines; these differences should be assessed serially to determine the impact of the guidelines on future clinical practice.


Subject(s)
Graves Disease/therapy , Professional Practice/statistics & numerical data , Adult , Data Collection , Endocrinology/legislation & jurisprudence , Endocrinology/organization & administration , Female , Geography , Global Health/statistics & numerical data , Graves Disease/epidemiology , Guideline Adherence/statistics & numerical data , Humans , Internet , Practice Guidelines as Topic , Societies, Medical/legislation & jurisprudence , Societies, Medical/statistics & numerical data , Surveys and Questionnaires , United States/epidemiology , Workforce
10.
Pediatr Diabetes ; 13 Suppl 16: 49-61, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22931224

ABSTRACT

INTRODUCTION: ISPAD guidelines recommend age appropriate diabetes education concepts for young patients and their families as well as tools for nutritional management, psychosocial assessment, and psychological advice but their implementation in Europe is presently unknown. METHODS: On the basis of a structured survey among the European SWEET members information on established tools and programs in national languages were analyzed using an extensive literature and desk search. These were differentiated according to five age-groups and five target groups (young people with diabetes, parents, and other close relations, carers in school and nursery, and healthcare professionals). RESULTS: Responses and original tools were received from 11 SWEET countries reflecting the European status in 2011. More or less structured information for parents, close relations, and carers in school or nursery are available in all 11 participating countries. However, only two countries followed the recommendations of having published a structured, curriculum lead, and evaluated program for different age-groups and carers. One of these was evaluated nationwide and funded by the respective National Health Care System after accreditation. In addition a huge variety of creative tools, e.g., booklets, leaflets, games, videos, and material for educating children of different age-groups and their parents are available - but most of them are not linked to a structured education program. CONCLUSIONS: Harmonizing and integrating these materials into quality assured structured holistic national education programs will be an important future task for the ongoing SWEET project. A comprehensive European diabetes educational toolbox is aimed to be published and continuously updated on the SWEET website.


Subject(s)
Diabetes Mellitus/therapy , Endocrinology/standards , Patient Education as Topic , Pediatrics/methods , Pediatrics/organization & administration , Accreditation/legislation & jurisprudence , Accreditation/methods , Adolescent , Child , Child, Preschool , Diabetes Mellitus/epidemiology , Endocrinology/education , Endocrinology/legislation & jurisprudence , Endocrinology/organization & administration , Europe/epidemiology , Humans , International Cooperation , Patient Care Team/legislation & jurisprudence , Patient Care Team/organization & administration , Patient Care Team/standards , Patient Education as Topic/legislation & jurisprudence , Patient Education as Topic/methods , Patient Education as Topic/organization & administration , Pediatrics/legislation & jurisprudence , Pediatrics/standards , Reference Standards , Standard of Care/organization & administration
11.
Pediatr Diabetes ; 13 Suppl 16: 20-8, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22931221

ABSTRACT

Education is the keystone of diabetes care, and structured self-management education is the key to a successful outcome. Existing guidelines provide comprehensive guidance on the various aspects of education and offer general and organizational principles of education, detailed curricula at different ages and stages of diabetes, and recommendations on models, methods, and tools to attain educative objectives. The International Society for Pediatric and Adolescent Diabetes guidelines give the most elaborate and detailed descriptions and recommendations on the practice of education, which other national guidelines address on specific aspects of education and care. The aim of the work package on education developed by Better Control in Paediatric and Adolescent Diabetes in the European Union: Working to Create Centers of Reference (SWEET) project was not to generate new guidelines but to evaluate how the existing guidelines were implemented in some pediatric diabetes reference centers. The SWEET members have completed a questionnaire that elaborates on the many aspects of delivery of education. This survey highlights a profound diversity of practices across centers in Europe, in terms of organization as well as the practices and the content of initial and continuing education. A toolbox is being developed within SWEET to facilitate exchanges on all aspects of education and to establish a process of validation of materials, tools, written structured age-adjusted programs, and evaluation procedures for the education of children and adolescents with diabetes.


Subject(s)
Diabetes Mellitus/therapy , European Union , Health Planning Guidelines , Parent-Child Relations , Patient Education as Topic/methods , Adolescent , Adult , Age Factors , Child , Data Collection , Diabetes Mellitus/epidemiology , Endocrinology/education , Endocrinology/legislation & jurisprudence , Endocrinology/organization & administration , Endocrinology/standards , European Union/organization & administration , Health Plan Implementation , Humans , Interdisciplinary Communication , Parents/education , Patient Education as Topic/legislation & jurisprudence , Patient Education as Topic/organization & administration , Patient Education as Topic/standards , Reference Standards , Standard of Care/legislation & jurisprudence , Standard of Care/organization & administration
12.
Pediatr Diabetes ; 13 Suppl 16: 39-48, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22931223

ABSTRACT

BACKGROUND: One of the most important tasks of the SWEET study is benchmarking the data collected. Information on the occurrence of the disease of diabetes, the treatment, and their outcomes in children from the different member states of European Union (EU) is crucial. How the collection of data is realized is essential, concerning both the technical issues and the results. The creation of SWEET Centers of Reference (CoR), all over Europe will be facilitated by the access to safe data collection, where legal aspects and privacy are ascertained. OBJECTIVE: To describe the rationale for- and the technical procedure in the data collection implementation, in the SWEET study. SUBJECTS: Selected data on all patients treated at SWEET CoR are collected. METHODS: The SWEET project data collection and management system, consists of modular components for data collection, online data interchange, and a database for statistical analysis. CONCLUSION: The SWEET study and the organization of CoR aims for the goal of offering an updated, secure, and continuous evaluation of diabetes treatment regimens for all children with diabetes in Europe. To support this goal, an appropriate and secure data management system as described in this paper has been created.


Subject(s)
Computer Security/legislation & jurisprudence , Confidentiality/legislation & jurisprudence , Data Collection , Diabetes Mellitus/epidemiology , Adolescent , Child , Computer Security/standards , Confidentiality/standards , Data Collection/instrumentation , Data Collection/legislation & jurisprudence , Data Collection/methods , Data Collection/standards , Databases, Factual/legislation & jurisprudence , Databases, Factual/standards , Diabetes Mellitus/therapy , Endocrinology/legislation & jurisprudence , Endocrinology/methods , Endocrinology/organization & administration , Endocrinology/standards , European Union/organization & administration , European Union/statistics & numerical data , Humans , International Cooperation/legislation & jurisprudence , Management Information Systems/legislation & jurisprudence , Management Information Systems/standards , Models, Biological , Reference Standards , Registries/standards , Registries/statistics & numerical data
14.
Diabetes Res Clin Pract ; 97(3): 425-31, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22513346

ABSTRACT

Diabetes is the fastest growing chronic condition in Australia, affecting 1.7 million Australians, requiring daily self-care, and known to reduce quantity and quality of life. On average, people with diabetes experience greater emotional distress than those without diabetes. One source of distress can be the language used to refer to diabetes, its management and the person with diabetes. The way verbal and written language is used reflects and shapes people's thoughts, beliefs and behaviours. Language has the power to persuade, change or reinforce beliefs and stereotypes - for better or worse. Words do more than reflect people's reality: they create reality and affect how people view the world and their diabetes. Language needs to engage people with diabetes and support their self-care efforts. Importantly, language that de-motivates or induces fear, guilt or distress needs to be avoided and countered. Diabetes Australia believes optimal communication increases the motivation, health and well-being of people with diabetes, and that careless or negative language can be de-motivating, is often inaccurate, and can be harmful. Diabetes Australia developed this position statement to encourage greater awareness of the language surrounding diabetes and provide recommendations for more careful and positive language use.


Subject(s)
Diabetes Mellitus/therapy , Endocrinology , Health Communication/methods , Information Dissemination/legislation & jurisprudence , Language , Practice Guidelines as Topic , Professional-Patient Relations , Societies, Medical/legislation & jurisprudence , Australia , Dissent and Disputes , Endocrinology/education , Endocrinology/legislation & jurisprudence , Endocrinology/organization & administration , Humans , Information Dissemination/methods , Needs Assessment , Societies, Medical/organization & administration , Terminology as Topic
16.
J Clin Endocrinol Metab ; 97(1): 16-38, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22223765

ABSTRACT

OBJECTIVE: The aim was to formulate practice guidelines on the management of hyperglycemia in hospitalized patients in the non-critical care setting. PARTICIPANTS: The Task Force was composed of a chair, selected by the Clinical Guidelines Subcommittee of The Endocrine Society, six additional experts, and a methodologist. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Endocrine Society members, American Diabetes Association, American Heart Association, American Association of Diabetes Educators, European Society of Endocrinology, and the Society of Hospital Medicine reviewed and commented on preliminary drafts of this guideline. CONCLUSIONS: Hyperglycemia is a common, serious, and costly health care problem in hospitalized patients. Observational and randomized controlled studies indicate that improvement in glycemic control results in lower rates of hospital complications in general medicine and surgery patients. Implementing a standardized sc insulin order set promoting the use of scheduled basal and nutritional insulin therapy is a key intervention in the inpatient management of diabetes. We provide recommendations for practical, achievable, and safe glycemic targets and describe protocols, procedures, and system improvements required to facilitate the achievement of glycemic goals in patients with hyperglycemia and diabetes admitted in non-critical care settings.


Subject(s)
Hospitalization , Hyperglycemia/therapy , Practice Guidelines as Topic , Blood Glucose Self-Monitoring/methods , Continuity of Patient Care , Critical Care , Endocrinology/legislation & jurisprudence , Endocrinology/methods , Endocrinology/organization & administration , Endocrinology/standards , Evidence-Based Practice/methods , Evidence-Based Practice/trends , Humans , Hypoglycemic Agents/therapeutic use , Inpatients , Insulin/administration & dosage , Insulin/therapeutic use , Intraoperative Care/methods , Monitoring, Physiologic/methods , Societies, Medical/legislation & jurisprudence
17.
Hormones (Athens) ; 10(3): 174-95, 2011.
Article in English | MEDLINE | ID: mdl-22001129

ABSTRACT

Targeting osteoblast may be the means of effectively improving both bone quality and mass, thus offering an intriguing alternative in the treatment of osteoporosis. Aside from injectable parathyroid hormone (PTH) and its novel preparations, PTH-related peptide (PTHrP), calcilytics, beta-adrenergic receptors, enhancement of Wnt signaling (mainly via sclerostin and Dickkopf-1 neutralization), regulation of low-density lipoprotein receptor-related protein (LPR) 5/osteoblast axis, activin, IGF-1, and bone morphogenic proteins (BMPs) are reviewed for their basic rationale and evidence of bone anabolic potential. Sclerostin neutralizing antibody, teriparatide transdermal patch, and PTHrP (1-36) are currently at an advanced stage of research. Safety and tissue specificity are the prerequisites in the development of a novel treatment, especially when addressing a chronic condition such as osteoporosis.


Subject(s)
Anabolic Agents/therapeutic use , Bone Density Conservation Agents/therapeutic use , Drug Delivery Systems/methods , Drugs, Investigational/therapeutic use , Osteoblasts/drug effects , Osteoporosis/drug therapy , Anabolic Agents/administration & dosage , Animals , Bone Density Conservation Agents/administration & dosage , Drug Approval , Drugs, Investigational/administration & dosage , Endocrinology/legislation & jurisprudence , Endocrinology/methods , Humans , Models, Biological , Osteoblasts/physiology
18.
J Assist Reprod Genet ; 28(11): 1105-9, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21912979

ABSTRACT

PURPOSE: Review of the legal and ethical basis for reproductive endocrinologists to refuse ovulation induction to patients with diminished ovarian reserve. METHODS: The Lexis-Nexis search engine was used to perform a legal review pertaining to refusal of treatment. Ethical opinions of medical organizations were also reviewed. RESULTS: Federal antidiscrimination laws provide legal recourse for patients with diminished ovarian reserve who are denied ovulation induction. However, the same laws also permit refusal of care when there is bona fide medical justification to decline services. In addition, the codes of ethics for relevant professional organizations support physicians' decisions to refuse treatment when treatment is futile. CONCLUSION: Although it is ethically and legally permissible to deny ovulation induction to patients with diminished ovarian reserve when medically justified, refusal may invite retaliatory litigation. Counseling remains a cornerstone in directing these patients to options with more potential for success, such as donor eggs and adoption.


Subject(s)
Endocrinology , Ovulation Induction/ethics , Reproductive Rights/ethics , Reproductive Rights/legislation & jurisprudence , Adoption/legislation & jurisprudence , Endocrinology/ethics , Endocrinology/legislation & jurisprudence , Ethical Analysis , Female , Humans , Tissue Donors/legislation & jurisprudence , Workforce
19.
Endocr Pract ; 17(3): 456-520, 2011.
Article in English | MEDLINE | ID: mdl-21700562

ABSTRACT

OBJECTIVE: Thyrotoxicosis has multiple etiologies, manifestations, and potential therapies. Appropriate treatment requires an accurate diagnosis and is influenced by coexisting medical conditions and patient preference. This article describes evidence-based clinical guidelines for the management of thyrotoxicosis that would be useful to generalist and subspeciality physicians and others providing care for patients with this condition. METHODS: The development of these guidelines was commissioned by the American Thyroid Association in association with the American Association of Clinical Endocrinologists. The American Thyroid Association and American Association of Clinical Endocrinologists assembled a task force of expert clinicians who authored this report. The task force examined relevant literature using a systematic PubMed search supplemented with additional published materials. An evidence-based medicine approach that incorporated the knowledge and experience of the panel was used to develop the text and a series of specific recommendations. The strength of the recommendations and the quality of evidence supporting each was rated according to the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation Group. RESULTS: Clinical topics addressed include the initial evaluation and management of thyrotoxicosis; management of Graves' hyperthyroidism using radioactive iodine, antithyroid drugs, or surgery; management of toxic multinodular goiter or toxic adenoma using radioactive iodine or surgery; Graves' disease in children, adolescents, or pregnant patients; subclinical hyperthyroidism; hyperthyroidism in patients with Graves' ophthalmopathy; and management of other miscellaneous causes of thyrotoxicosis. CONCLUSIONS: One hundred evidence-based recommendations were developed to aid in the care of patients with thyrotoxicosis and to share what the task force believes is current, rational, and optimal medical practice.


Subject(s)
Hyperthyroidism/complications , Hyperthyroidism/therapy , Practice Guidelines as Topic , Thyrotoxicosis/etiology , Thyrotoxicosis/therapy , Adolescent , Endocrinology/legislation & jurisprudence , Endocrinology/methods , Evidence-Based Medicine , Female , Graves Disease/complications , Graves Disease/etiology , Graves Disease/therapy , Humans , Pregnancy , Societies, Medical/legislation & jurisprudence , United States
20.
Eur J Endocrinol ; 165(2): 171-6, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21602318

ABSTRACT

Bariatric and metabolic surgery is experiencing a noteworthy increase worldwide in recent years, but protocols and consensus published in the past decade have not yet established clear evidence-based clinical recommendations. The Endocrine Society, with the participation of the European Society of Endocrinology, has promoted the creation of an expert panel to propose a clinical practice guideline for postoperative management of patients, candidates to bariatric surgery, that places a particular emphasis on evidence-based medical aspects. The main arguments reflected in those recommendations are set out in this article and are subject to analysis and discussion from the specific viewpoint of the current European experience.


Subject(s)
Bariatric Surgery/rehabilitation , Endocrinology/legislation & jurisprudence , Obesity/surgery , Postoperative Care/legislation & jurisprudence , Practice Guidelines as Topic , Societies, Scientific/legislation & jurisprudence , Diabetes Complications/therapy , Diet Therapy , Endocrine System/physiology , Endocrinology/organization & administration , Europe , Evidence-Based Practice , Follow-Up Studies , Humans , Nutritional Physiological Phenomena , Obesity/complications , Obesity/physiopathology , Obesity/prevention & control , Postoperative Care/standards , Weight Gain/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...